United States Patent 7,081,250: Oxybutynin Transdermal Patch Claims, Expiration, and Patent Landscape

U.S. Patent No. 7,081,250 covers a transdermal oxybutynin product and its use to reduce anticholinergic adverse effects by controlling the plasma exposure ratio between oxybutynin and N-desethyloxybutynin. The claims are directed to two protected categories: treatment methods and a transdermal article of manufacture. The patent does not broadly cover all oxybutynin patches. Infringement requires a patch using a covered permeation enhancer and producing the claimed oxybutynin-to-metabolite AUC ratio.

The patent has expired. Its commercial significance now lies in the scope of historical Orange Book protection for Oxytrol and in the technical boundaries that remain relevant to generic design-around analysis.

What does U.S. Patent 7,081,250 protect?

Patent 7,081,250 protects transdermal administration of oxybutynin under a pharmacokinetic framework. The central limitation is not merely delivery through the skin. The patch must produce a plasma AUC ratio of oxybutynin to N-desethyloxybutynin within a specified range.

Feature	Scope of claim
Active ingredient	Oxybutynin
Dosage form	Transdermal patch
Patient	Human subject
Indication	Overactive bladder
Claimed benefit	Minimizing anticholinergic or antimuscarinic adverse drug experiences
Metabolite	N-desethyloxybutynin
Broad AUC ratio	About 0.5:1 to about 5:1
Intermediate AUC ratio	About 1:1 to about 5:1
Narrow AUC ratio	About 0.8:1 to about 1.5:1
Enhancer classes	Fatty acids, fatty acid esters, fatty alcohols, lactic- or glycolic-acid fatty acid esters, glycerol mono- or diesters, short-chain alcohols, and mixtures
Stereochemistry	Racemic oxybutynin, R-oxybutynin, and R- or S-N-desethyloxybutynin

The patent reflects the pharmacology of oral oxybutynin. Oral administration produces substantial first-pass metabolism to N-desethyloxybutynin, a metabolite associated with anticholinergic effects, particularly dry mouth. Transdermal administration reduces first-pass metabolism and increases the relative exposure to parent oxybutynin.

How do claims 1 through 11 operate?

Claims 1 through 11 are method-of-treatment claims. Claim 1 is the independent method claim. It requires all of the following:

Treatment of a human subject with overactive bladder.
Administration of oxybutynin through a transdermal patch.
An effective amount of a listed permeation enhancer.
A plasma oxybutynin-to-N-desethyloxybutynin AUC ratio of approximately 0.5:1 to 5:1.
A purpose or result involving minimization of an anticholinergic or antimuscarinic adverse drug experience.

The dependent claims narrow the composition or pharmacokinetic result.

Claim	Limitation
1	Broad treatment method; AUC ratio about 0.5:1 to 5:1; listed enhancer
2	AUC ratio about 1:1 to 5:1
3	AUC ratio about 0.8:1 to 1.5:1
4	R-, S-, or combined N-desethyloxybutynin
5	Mixture of R- and S-oxybutynin
6	R-oxybutynin
7	Fatty-acid enhancer
8	Fatty-acid ester enhancer
9	Fatty-alcohol enhancer
10	Short-chain alcohol enhancer
11	Glycerol monoester enhancer

Claim 6 is particularly narrow because it requires R-oxybutynin rather than a racemic mixture. A product containing conventional racemic oxybutynin would not meet that limitation, although it could still fall within claim 1 or claim 5.

What do claims 12 through 22 cover?

Claims 12 through 22 cover an article of manufacture, meaning the transdermal patch itself rather than the act of treating a patient.

Claim 12 requires a patch containing:

oxybutynin;
a listed permeation enhancer;
a design that produces the claimed AUC ratio after administration; and
a capability to minimize an anticholinergic or antimuscarinic adverse drug experience.

The article claims provide a product-based infringement theory. A generic manufacturer could face a different analysis under the method claims and article claims. A manufacturer, seller, or importer may be exposed through the patch composition and labeling, while a healthcare provider or patient-use theory would focus more directly on the method claims.

Claims 13 through 22 mirror the narrowing structure of claims 2 through 11. The product claims therefore do not add a materially different technical concept. They extend the claim set from treatment conduct to the patch as a commercial article.

How strong is the AUC-ratio limitation?

The AUC ratio is the principal technical limitation and the principal vulnerability of the claims.

AUC is an exposure measurement calculated from plasma concentration over time. The patent claims require comparison of oxybutynin exposure with exposure to N-desethyloxybutynin. The relevant ratio is:

[ \text{AUC ratio} = \frac{\text{AUC of oxybutynin}}{\text{AUC of N-desethyloxybutynin}} ]

A generic patch would not necessarily infringe merely because it uses oxybutynin and produces fewer anticholinergic effects. The relevant product would need to produce the claimed ratio, subject to the ordinary rules governing claim construction, inherent infringement, and proof of pharmacokinetic performance.

The limitation creates several litigation issues:

whether the ratio must be measured in every patient or can be established through representative clinical data;
whether “about” permits a numerical tolerance;
whether the ratio is measured over a defined dosing interval;
whether the claimed ratio is an inherent property of the patch;
whether variability among subjects prevents a reliable infringement finding; and
whether the listed enhancer is present in an “effective amount.”

The use of “about” creates flexibility but does not eliminate the need to prove a qualifying numerical range. The narrowest claims, particularly claim 3 and claim 14, may be easier to avoid through formulation or dose selection that produces a ratio outside approximately 0.8:1 to 1.5:1.

What formulations are protected by Patent 7,081,250?

The patent claims enhancer classes rather than a single named formulation. The covered classes include:

fatty acids;
fatty acid esters;
fatty alcohols;
fatty acid esters of lactic acid or glycolic acid;
glycerol monoesters;
glycerol diesters;
short-chain alcohols; and
mixtures of those materials.

The phrase “consisting essentially of” generally permits components that do not materially affect the basic and novel characteristics of the composition. It is narrower than “comprising” but broader than “consisting of.” The legal question would be whether an added excipient materially changes the claimed transdermal composition or its relevant performance.

The claims do not expressly require a particular:

backing layer;
adhesive;
release liner;
reservoir or matrix architecture;
oxybutynin concentration;
patch area;
wear duration;
nominal delivery rate; or
commercial brand.

That breadth increases the potential reach across patch architectures. The AUC and enhancer limitations narrow the practical scope.

Does the patent cover Oxytrol?

Patent 7,081,250 was part of the patent estate associated with transdermal oxybutynin products, including Oxytrol. Oxytrol is a transdermal oxybutynin system approved by the FDA for overactive bladder. The prescription product was approved under NDA 021351; an over-the-counter Oxytrol product was later approved for women under an FDA supplemental application pathway.

The patent’s claims align with the commercial rationale for Oxytrol: transdermal oxybutynin can reduce formation and systemic exposure of N-desethyloxybutynin compared with oral administration.

The patent should not be treated as covering all aspects of Oxytrol automatically. Product-specific infringement would require mapping the commercial patch to:

the oxybutynin composition;
a listed enhancer;
the claimed AUC ratio; and
the relevant claim category.

FDA approval and Orange Book listing are separate from infringement. FDA labeling may provide evidence concerning intended use, but regulatory approval does not itself establish that every patent claim is infringed.

When did Patent 7,081,250 expire?

Patent 7,081,250 is expired. Public patent records identify an October 2001 nonprovisional filing and a patent term running approximately 20 years from the relevant filing date, subject to applicable patent-term adjustments, disclaimers, and any regulatory extension. The patent issued on July 25, 2006.

Milestone	Date
Patent issued	July 25, 2006
Standard 20-year term from relevant filing	Approximately October 2021
Current status	Expired

The precise effective expiration date should be determined from the USPTO patent-term record and any terminal disclaimer or patent-term adjustment associated with the family. The patent is not a current blocking patent for U.S. commercial launch.

Patent expiration eliminates ordinary enforcement for post-expiration conduct. It does not erase historical infringement exposure during the enforceable term, and it does not invalidate separate patents in the same oxybutynin product family.

What was the Orange Book status of Patent 7,081,250?

Patent 7,081,250 was associated with the regulatory patent estate for transdermal oxybutynin products. Orange Book relevance depends on the specific NDA, listed product, patent-use code, and timing of the listing.

Orange Book-listed patents can create an ANDA certification obligation under the Hatch-Waxman Act. A generic applicant may be required to submit:

a Paragraph I certification if no patent information is listed;
a Paragraph II certification if the patent has expired;
a Paragraph III certification accepting a later launch date; or
a Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed.

For an expired patent, the relevant certification is generally Paragraph II. During the enforceable period, a Paragraph IV certification could trigger a patent-infringement action under 35 U.S.C. § 271(e)(2).

Were Paragraph IV challenges relevant?

Paragraph IV risk was relevant while the patent remained listed and unexpired. The principal attack points would have included:

lack of written description or enablement for the full AUC range;
indefiniteness of the terms “about,” “effective amount,” and “minimizing”;
obviousness based on known transdermal oxybutynin systems and permeation enhancers;
anticipation by prior transdermal oxybutynin formulations;
failure to demonstrate that the claimed AUC ratio is consistently achieved; and
noninfringement based on an enhancer, patch architecture, or pharmacokinetic ratio outside the claim.

The AUC limitation could support validity by tying the claims to a pharmacological result. It could also support an obviousness challenge if prior art disclosed transdermal oxybutynin and the claimed ratio was an expected consequence of avoiding first-pass metabolism.

Which companies challenged or competed with Oxytrol?

The commercial competitive field included:

Product or category	Company or sponsor	Relevance
Oxytrol transdermal system	Watson, later Actavis/Allergan-related entities	Reference transdermal product
Generic oxybutynin transdermal systems	Multiple ANDA sponsors over time	Direct competition after regulatory and patent barriers
Ditropan and generic oral oxybutynin	Multiple manufacturers	Competes on price but has different pharmacokinetics
Gelnique	Antares and subsequent commercial partners	Oxybutynin topical gel; separate formulation and patent estate
Oxybutynin extended-release tablets	Multiple generic manufacturers	Oral alternative
Mirabegron and other overactive-bladder therapies	Astellas and other sponsors	Non-anticholinergic or alternative pharmacology

The main commercial distinction was between transdermal oxybutynin and oral oxybutynin. Oral products generally faced extensive generic competition earlier, while transdermal products depended on device, formulation, regulatory, and patent barriers.

What generic launch risks remain?

Patent 7,081,250 itself presents no current U.S. launch bar because it has expired. Remaining risks may arise from:

other unexpired patents covering a specific patch construction;
patents covering adhesives, backing layers, or delivery matrices;
formulation patents for a particular oxybutynin concentration or release profile;
method-of-use patents with narrower patient or dosing limitations;
FDA requirements for bioequivalence or comparative pharmacokinetic data;
ANDA labeling constraints; and
manufacturing know-how involving coating, drying, lamination, and dose uniformity.

A generic manufacturer can design around the expired patent by using a nonlisted enhancer, a different patch construction, or a formulation that does not produce the claimed ratio. Those strategies were more important before expiration because they could avoid a Paragraph IV dispute. They now matter mainly for freedom-to-operate against other family members or unrelated patents.

Does biosimilar risk apply?

No. Oxybutynin is a small-molecule drug, not a biologic. Biosimilar pathways under the Public Health Service Act do not apply. Competition proceeds through the ANDA pathway or, for certain products and indications, other small-molecule FDA pathways.

The relevant regulatory risks are generic-drug bioequivalence, product quality, transdermal delivery performance, adhesion, residual drug, dose uniformity, and labeling.

How does Patent 7,081,250 compare with other oxybutynin patents?

Patent 7,081,250 is distinguished by its pharmacokinetic and clinical-result limitations.

Patent type	Principal protection	Relationship to 7,081,250
Transdermal composition patent	Patch ingredients and structure	May overlap in product construction
Pharmacokinetic method patent	Parent-to-metabolite exposure ratio	Core subject of 7,081,250
Method-of-use patent	Treating overactive bladder or reducing adverse effects	May overlap in use but require different limitations
Gel formulation patent	Topical oxybutynin gel	Separate dosage form
Manufacturing patent	Coating, lamination, or assembly process	Potentially independent barrier
Oral oxybutynin patent	Tablets, extended release, or salts	Generally outside the patch claims

The patent estate should therefore be analyzed by claim type rather than by the active ingredient alone. A company can avoid the claims of 7,081,250 and still encounter a separate formulation or manufacturing patent.

Key Takeaways

Patent 7,081,250 covers oxybutynin transdermal treatment and patch products that produce an oxybutynin-to-N-desethyloxybutynin AUC ratio of approximately 0.5:1 to 5:1.
The patent requires a listed class of permeation enhancer.
Claims 1 through 11 cover treatment methods; claims 12 through 22 cover the patch as an article of manufacture.
The narrowest claims require an AUC ratio of approximately 0.8:1 to 1.5:1.
R-oxybutynin and stereoisomer-specific metabolite claims are narrower than the broad racemic claims.
The patent is expired and is not a current U.S. exclusivity barrier.
Generic competition is governed by other patents, FDA transdermal-product requirements, and manufacturing constraints.
Biosimilar analysis does not apply because oxybutynin is a small molecule.
The patent’s strongest historical differentiator was the pharmacokinetic relationship between oxybutynin and N-desethyloxybutynin, not the use of oxybutynin alone.

FAQs

What is the main infringement issue under U.S. Patent 7,081,250?

The main issue is whether the accused patch uses a claimed permeation enhancer and produces the required plasma AUC ratio between oxybutynin and N-desethyloxybutynin.

Does an oxybutynin gel infringe Patent 7,081,250?

Not necessarily. The asserted claims require a transdermal patch. A topical gel would need to satisfy the claim’s patch limitation and all other limitations to create literal infringement.

Does oral oxybutynin infringe this patent?

No ordinary oral oxybutynin product would satisfy the express transdermal-patch limitation.

Can a generic manufacturer avoid the patent by changing the permeation enhancer?

A different enhancer may avoid literal infringement if it is outside the claimed enhancer classes. The analysis must also consider mixtures, equivalents, and other patents in the product family.

Is an AUC ratio alone enough to establish infringement?

No. The accused product must satisfy the complete claim, including the transdermal patch, oxybutynin, the applicable enhancer limitation, the AUC ratio, and any treatment or product limitations.

References

United States Patent and Trademark Office. (2006). U.S. Patent No. 7,081,250, Transdermal oxybutynin compositions.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
Patent Act, 35 U.S.C. §§ 154, 271, 282.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	488233	⤷ Start Trial
Australia	2001253782	⤷ Start Trial
Australia	2003287377	⤷ Start Trial
Australia	2003294239	⤷ Start Trial
Australia	2010200418	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,081,250

Summary for Patent: 7,081,250